Mechanistically, USP29 promotes sorafenib resistance in HCC cells by upregulating glycolysis, thus opening a new avenue for therapeutic targeting of patients with sorafenib-resistant HCC (158). The gene discussed is USP29; the disease is hepatocellular carcinoma.